Skip to content Skip to footer
Subscribe Now
Telix Pharmaceuticals
NEWS

Telix Reports First US Patients Dosed with FDA-Approved Pixclara for Glioma Imaging

Shots: Telix Pharmaceuticals reported that the first pts. in the US have been dosed with Pixclara (floretyrosine F-18), marking the start of commercial availability of the FDA-approved PET imaging drug for glioma Pixclara (IV) is indicated for use with PET to differentiate recurrent or progressive glioma from treatment-related changes in adults and pediatric patients one…
October 6, 2026

Read more

NEWS

GE HealthCare to Acquire SOFIE Biosciences for $945M to Expand US PET Radiopharmaceutical Supply

Shots: GE HealthCare entered into a definitive agreement to acquire SOFIE Biosciences from Trilantic North America for $945M in cash, with the transaction expected to close in 1H’27, subject to regulatory approvals and other closing conditions. If completed, SOFIE will become part of GE HealthCare’s PDx segment The acquisition will establish GE HealthCare’s footprint in the…
October 6, 2026

Read more

MAGAZINE

PharmaShots Magazine-Sep-2026 Edition

Shots: This edition explores The Next Frontier: AI Transforming Healthcare Delivery, examining how artificial intelligence, machine learning, predictive analytics, connected devices, real-world data, and digital health platforms are reshaping healthcare delivery from reactive to more predictive, proactive, connected, and patient-centered models of care. Through expert perspectives, feature stories, and industry insights, we examine how AI…
September 17, 2026

Read more

CXO TALKS

Cytek Biosciences on Redefining Flow Cytometry Excellence | PharmaShots CXO Talks

What happens when cell analysis moves beyond simply measuring more to understanding more? In the latest episode of PharmaShots CXO Talks, Wenbin Jiang, CEO and Chairman of the Board, and William McCombe, Chief Financial Officer, Cytek Biosciences, explore how advances in flow cytometry, AI, imaging, and cloud-based analytics are reshaping the way researchers understand cells.…
September 16, 2026

Read more

EVENTS

Digi-Tech Pharma & AI 2027 | May 11-12 | London, UK

The pharmaceutical and healthcare industries are entering a new era of technology-led transformation, with artificial intelligence, machine learning, data science, informatics, and advanced data management reshaping how medicines are discovered, developed, and delivered. Against this backdrop, Digi-Tech Pharma & AI 2027 will bring together senior professionals, technology leaders, decision-makers, and innovators from the pharmaceutical, biotechnology,…
August 19, 2026

Read more

EXCLUSIVE

Oncolytics Biotech’s Next Chapter: Jared Kelly on Advancing Pelareorep Toward Approval  

Shots  Pelareorep is gaining regulatory momentum through multiple FDA interactions and Fast Track designations, providing greater clarity around potential registration pathways and shaping Oncolytics’ clinical development and partnership strategy.  REO-033 could mark a pivotal step toward registration as the randomized study in RAS-mutant MSS metastatic colorectal cancer builds on encouraging clinical data and has the potential to become…
August 17, 2026

Read more

MAGAZINE

PharmaShots Magazine-Aug-2026 Edition

Shots:  This edition explores Tailored Therapy, Smarter Decisions: AI in Personalized Medicine, highlighting how artificial intelligence, machine learning, multi-omics, real-world data, and predictive analytics are transforming personalized medicine into a more precise, data-driven, and patient-centric approach to care, enabling better patient stratification, treatment selection, and clinical decision-making. Through expert perspectives, feature stories, and industry insights,…
August 13, 2026

Read more

INSIGHTS+

The US FDA New Drug Approvals in July 2026 

Shots:  The US FDA approved six notable therapies in July 2026 across nephrology, oncology, cardiometabolic disease, ophthalmology, and neuropsychiatry, highlighting continued progress in specialty and chronic disease treatment.   Key approvals included Trutakna (atacicept) for IgA nephropathy, Revtorpyk (gedatolisib) for HR+/HER2- breast cancer, Lipfendra (enlicitide) for hypercholesterolemia, Jideytro (zidesamtinib) for ROS1-positive NSCLC, Lytenava (bevacizumab-vikg) for wet AMD, and Simtriyo (centanafadine) for ADHD, expanding treatment options across diverse patient…
August 11, 2026

Read more

VIEWPOINTS

A Promise Made at Six: The Winding Road to Cancer Research

An Interview with Priyanka Joshi, Associate Scientist in Analytical Development Introduction Cancer remains one of the world's greatest healthcare challenges, driving scientists to develop more effective and precise treatment approaches. Among the most promising innovations are cell therapies, which harness the body's own immune system to fight cancer. Behind these advances are scientists working to…
August 5, 2026

Read more

Load more